246250 — SLS Bio Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩36bn
- KR₩29bn
- KR₩9bn
- 72
- 27
- 10
- 25
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7,420 | 8,722 | 8,243 | 10,752 | 9,023 |
Cost of Revenue | |||||
Gross Profit | 2,877 | 2,251 | 2,179 | 4,210 | 3,111 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 6,336 | 9,437 | 7,816 | 8,328 | 7,992 |
Operating Profit | 1,084 | -715 | 426 | 2,424 | 1,031 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 684 | -886 | 259 | 2,225 | 1,057 |
Provision for Income Taxes | |||||
Net Income After Taxes | 627 | -678 | 57.9 | 2,826 | 1,434 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 627 | -678 | 57.9 | 2,826 | 1,434 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 627 | -678 | 57.9 | 2,826 | 1,434 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 91.8 | -99.4 | 7.32 | 408 | 204 |
Dividends per Share |